STARNBERG, Germany, March 20, 2017 /PRNewswire/ -- PARI Pharma, a company focused on optimization of drug-device combinations, has licensed its first-in-class inhalation development program for ...

MONTEREY, Calif., Nov. 26 PARI Pharma's eFlow electronicnebulizer was included in Gilead's (Nasdaq: GILD) recent New Drug Application(NDA) submittal to the U.S. Food and Drug Administration (FDA) for ...

MONTEREY, Calif., April 17 /PRNewswire/ -- An optimized PARI eFlow platform nebulizer will be delivering Alnylam's ALN-RSV01 in a Phase II human clinical trial that has begun enrolling patients.

MONTEREY, Calif., Oct. 6 Today, PARI Pharma GmbH willunveil a prototype Closed System using eFlow Technology that uses single doseampoules to control medication used in the nebulizer system. By ...

LANGHORNE, Pa., December 02, 2025--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the European ...

STARNBERG, Germany, June 7, 2016 /PRNewswire/ -- PARI Pharma, a company focused on the development of advanced aerosol therapies using eFlow Technology, announces that its proprietary closed eFlow ...

PARI's eFlow, an advanced electronic nebulizer, was optimized and used to deliver Alnylam's ALN-RSV01 in a Phase I human clinical trial. Results of the Phase I trial were announced at the 18th Annual ...